PepGen Inc. Common Stock (PEPG) Stock Price
PEPGStock
$3.42+141.67%52W
Market Cap$236.90M
P/E—
PEG Ratio—
Div yield—
Beta1.93
PEPG Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-62.47%
Price vs S&P 500 (4W)71.27%
VGM Score75.74
PEPG Earnings Surprise History
Q2 25-0.70est. -0.86
Q3 25-0.52est. -0.56
Q4 25-0.27est. -0.39
Q2 26-0.26est. -0.28
PEPG Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.31
4.31
4.29
4.29
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PEPGPepGen Inc. Common Stock | — | — | B | $3.42 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About PepGen Inc. Common Stock
PepGen is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases using its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. The EDO platform improves tissue penetration and cellular uptake of therapeutic oligonucleotides across multiple target tissues, including skeletal and cardiac muscle as well as the central nervous system, as demonstrated in preclinical studies. The company has multiple EDO-based candidates in development.